Corcept Therapeutics (CORT) Tax Provisions (2017 - 2026)

Corcept Therapeutics has disclosed Tax Provisions across 10 years of filings, most recently posting -$13.0 million for Q1 2026.

• Tax Provisions for Q1 2026 came in at -$13.0 million, down 18.84% year-over-year; the trailing twelve-month figure through Mar 2026 was -$35.2 million (down 1765.75% YoY), and the FY2025 annual result was -$33.2 million, down 263.62% from the prior year.
• Tax Provisions came in at -$13.0 million for Q1 2026 at Corcept Therapeutics, up from -$14.4 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $7.7 million in Q4 2022 to a low of -$14.4 million in Q4 2025.
• The 5-year median for Tax Provisions is $4.1 million (2022), against an average of $434882.4.
• Across the five-year window, Tax Provisions jumped 412.16% in 2023 and plunged 1284.35% in 2025, its largest moves.
• Corcept Therapeutics' Tax Provisions stood at $7.7 million in 2022, then retreated by 29.4% to $5.4 million in 2023, then plunged by 77.59% to $1.2 million in 2024, then slumped by 1284.35% to -$14.4 million in 2025, then rose by 9.9% to -$13.0 million in 2026.
• The last three Tax Provisions figures came in at -$13.0 million (Q1 2026), -$14.4 million (Q4 2025), and -$4.4 million (Q3 2025), per Business Quant data.